Clinical trials: Frontline
Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Trial name
- NCT02844582
- Testing
- Cabazitaxel, Prednisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Davis
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
This is a Phase II, open label, single arm, multi-centre study investigating the safety and efficacy of ofatumumab plus bendamustine in subjects with untreated or relapsed CLL.
- Trial name
- NCT01520922
- Testing
- Ofatumumab, Bendamustine
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
This phase II trial studies how well combination chemotherapy and inotuzumab ozogamicin work in treating patients with B acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Trial name
- NCT03488225
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side…
- Trial name
- NCT00843310
- Testing
- Lenalidomide (Revlimid), Melphalan, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma
- Trial name
- NCT01642251
- Testing
- Cisplatin, Etoposide, Veliparib
- Where
- 428 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Study to support the mental and physical well-being of US health care workers during the COVID-19 pandemic and ensure high-quality care for patients through Stress First Aid.
- Trial name
- COVER-HCW (NCT04723576)
- Testing
- Stress First Aid
- Where
- 2 sites in United States
- Volunteers
- 7,444 people, healthy volunteers welcome
- Sponsor
- RAND
Peripheral T-cell Lymphoma
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT04569032
- Testing
- brentuximab vedotin, cyclophosphamide, doxorubicin
- Where
- 63 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Leukemia
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn more about the characteristics of CLL, including genes and chromosome abnormalities and proteins expressed by the leukemia cells, which may help doctors predict if patients who…
- Trial name
- NCT00759798
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual…
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- MERIT (NCT02649387)
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04214249
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well combination chemotherapy and ofatumumab work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma
- Trial name
- NCT01363128
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- M.D. Anderson Cancer Center
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma.
- Conditions
- Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01920932
- Testing
- brentuximab vedotin, etoposide, prednisone
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- St. Jude Children's Research Hospital
Mantle Cell Lymphoma
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
This is a multi-arm phase 2 study to evaluate the preliminary evidence of efficacy and safety of the combination of acalabrutinib, lenalidomide and rituximab (ALR) and acalabrutinib, lenalidomide and obinutuzumab (ALO) in…
- Trial name
- NCT03863184
- Testing
- Acalabrutinib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Weill Medical College of Cornell University
Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin]…
- Trial name
- NCT01712490
- Testing
- brentuximab vedotin, doxorubicin, bleomycin
- Where
- 215 sites in United States, Australia and 19 more
- Volunteers
- 1,334 people
- Sponsor
- Takeda
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older.
- Trial name
- NCT00778375
- Testing
- Clofarabine, Cytarabine, Decitabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure.
- Conditions
- Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells, Blasts Under 30 Percent of Peripheral Blood White Cells
- Trial name
- NCT02906696
- Testing
- Bosutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth…
- Trial name
- NCT00523848
- Testing
- bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Roswell Park Cancer Institute